Renal Cancer - Results from #480

Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer. February 16, 2024

Disruption of Autophagic Flux and Treatment with the PDPK1 Inhibitor GSK2334470 Synergistically Inhibit Renal Cell Carcinoma Pathogenesis. February 16, 2024

Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry. February 15, 2024

RNA-binding protein IGF2BP2 suppresses metastasis of clear cell renal cell carcinoma by enhancing CKB mRNA stability and expression. February 15, 2024

NAA10 gene expression is associated with mesenchymal transition, dedifferentiation, and progression of clear cell renal cell carcinoma. February 14, 2024

Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI. February 14, 2024

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma. February 13, 2024

Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma. February 13, 2024

Targeting NPC1 in Renal Cell Carcinoma. February 12, 2024

Non-Metastatic Clear Cell Renal Cell Carcinoma Immune Cell Infiltration Heterogeneity and Prognostic Ability in Patients Following Surgery. February 12, 2024

Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study. February 9, 2024

Urine cytology in the detection of renal cell carcinomas - a territory-wide multi-institutional retrospective review of more than 2 decades. February 9, 2024

Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma. February 8, 2024

Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence risk. February 8, 2024

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist February 7, 2024

Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma. February 7, 2024

Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. February 7, 2024

Recurrent MTOR Mutations in Renal Cell Carcinoma With Fibromyomatous Stroma: A Report of 2 Tumors. February 6, 2024

Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma. February 6, 2024

The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients. February 5, 2024

Page 25 of 455